Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14140176 | 0.71 | CA1 (0.30) | CA1CA2 | |
| SCHEMBL20364512 | 0.69 | HTT (0.53) | — | |
| SCHEMBL6347129 | 0.67 | — | — | |
| SCHEMBL24810082 | 0.64 | POLB (0.41) | — | |
| SCHEMBL28939794 | 0.63 | — | — | |
| SCHEMBL28142047 | 0.63 | CA1 (0.38) | CA1CA2 | |
| SCHEMBL13698754 | 0.61 | CA1 (0.37) | CA1CA2 | |
| SCHEMBL31713762 | 0.61 | HTT (0.52) | CA1CA2 | |
| SCHEMBL22494211 | 0.61 | — | — | |
| SCHEMBL3585438 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509453-B2 | BRM/BRG1 inhibitors and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250333406-A1 | SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYSOWAY THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-20220119378-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509453-B2 | BRM/BRG1 inhibitors and uses thereof | SMARCC1, SMARCC2, SMARCA1 | CA1 4180/4885CA2 4352/4885 |
| US-20250333406-A1 | SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | STOML2, ATP2A3, ATP2A1 | CA1 2863/4885CA2 304/4885 |
| US-20220119378-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | CA1 4780/4885CA2 4715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.